REBECCA ANTWI-KISSEADOO: Open Payments
NPI 1962240796 · SUFFOLK, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,171 in 56 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $244 · 2025 $1,171
Food & beverage: $1,171
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 5 | $215 |
| Neurocrine BioSciences, Inc. | 4 | $188 |
| Otsuka America Pharmaceutical, Inc. | 16 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $157 |
| Janssen Pharmaceuticals, Inc | 4 | $101 |
| Alkermes, Inc. | 5 | $88 |
| ABBVIE INC. | 4 | $80 |
| Lundbeck LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $39 |
Products named: COBENFY, INGREZZA, REXULTI, CAPLYTA, ARISTADA, VRAYLAR, INVEGA SUSTENNA, SPRAVATO.
Industry payments across VA — which companies pay providers there.
